Recently, Ziltivekimab, a fully human monoclonal antibody directed against the IL-6 ligand, was shown to markedly reduced biomarkers of inflammation and thrombosis relevant to atherosclerosis in RESCUE trial [108, 109]. The gene discussed is IL6; the disease is atherosclerosis.